ロード中...
Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients
AIMS: Rituximab is a monoclonal antibody directed against CD20, which is approved in rheumatoid arthritis (RA). This study aimed at assessing the influence of CD19+ cell counts as target‐antigen amount, and of immunoglobulin G (IgG) serum concentrations on rituximab pharmacokinetics in RA patients....
保存先:
| 出版年: | Br J Clin Pharmacol |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5510084/ https://ncbi.nlm.nih.gov/pubmed/28230269 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13270 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|